epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-301, Phase III. Recruiting
Non-small cell lung cancer, second line
NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.
QTLs at a glance
Data to September 30th 2026. Each measure links to its chart below.
Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.
Rank
QTL
Likelihood
Impact
Why it is likely here
Watched at sites by
Warning
Limit
Critical
1
Ineligible patients randomisedEvidence grade B
2
2
Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two; Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
Study drug at the siteTighter KRI threshold at sites in Turkey, for currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026). The QTL itself stays study-wide.
12.5%
15%
22%
Ineligible patients randomised
Within range% of patients; benchmark median 3.2%
Show data
Ineligible patients randomised: running rate by month
Missing primary endpoint data: running rate by month
Month
Patients
Rate
Jan 2026
1
0%
Apr 2026
12
8.3%
Jul 2026
45
4.4%
Oct 2026
80
2.5%
The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it
Lost to follow-up or withdrew consent
Within range% of patients; benchmark median 3.7%
Show data
Lost to follow-up or withdrew consent: running rate by month
Month
Patients
Rate
Jul 2025
1
0%
Oct 2025
12
0%
Jan 2026
45
0%
Apr 2026
80
0%
Jul 2026
124
0%
Oct 2026
171
0.6%
epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status
Stopped study treatment early
Within range% of patients; benchmark median 10.7%
Show data
Stopped study treatment early: running rate by month
Month
Patients
Rate
Jul 2025
1
0%
Oct 2025
12
0%
Jan 2026
45
0%
Apr 2026
80
0%
Jul 2026
124
2.4%
Oct 2026
171
2.3%
epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power
Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).
Breaches and decisions
No QTL in EPI-301 has passed its early-warning line, so nothing needs evaluating.
Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.